High-grade sarcomatous overgrowth in solitary fibrous tumors: A clinicopathologic study of 10 cases

American Journal of Surgical Pathology

Volumn 36, Issue 8, 2012, Pages 1202-1215

  Collini, Paola ^a   Negri, Tiziana ^a   Barisella, Marta ^a   Palassini, Elena ^b   Tarantino, Eva ^a   Pastorino, Ugo ^a   Gronchi, Alessandro ^a   Stacchiotti, Silvia ^b   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Department of Clinical Oncology ^*  (Italy)

Author keywords

immunohistochemistry; mTOR effectors; sarcomatous overgrowth; solitary fibrous tumor

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOPHENOTYPING; MALE; METABOLISM; MULTIPLE CANCER; PATHOLOGY; RETROSPECTIVE STUDY; SARCOMA; SOLITARY FIBROUS TUMOR;

ADULT; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM GRADING; NEOPLASMS, MULTIPLE PRIMARY; RETROSPECTIVE STUDIES; SARCOMA; SOLITARY FIBROUS TUMORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863822848     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31825748f0     Document Type: Article

References (36)

1. Armengol G, Rojo F, Castellv́ J, et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res. 2007;67:7551-7555. (Pubitemid 47281345)
2. Caron E, Ghosh S, Matsuoka Y, et al. A comprehensive map of the mTOR signaling network. Mol Syst Biol. 2010;6:453-467.
3. Chan G, Horton PJ, Thyssen S, et al. Malignant transformation of a solitary fibrous tumor of the liver and intractable hypoglycaemia. J Hepatobiliary Pancreat Surg. 2007;14:595-599. (Pubitemid 350201474)
4. Culjkovic B, Tan K, Orolicki S, et al. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol. 2008;181:51-63. (Pubitemid 351519764)
5. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13:640-658. (Pubitemid 19185450)
6. Fenton TR, Gout IT. Functions and regulation of the 70 kDa ribosomal S6 kinases. Int J Biochem Cell Biol. 2011;43:47-59.
7. Fine SW, McCarthy DM, Chan TY, et al. Malignant solitary fibrous tumor of the kidney. Report of a case and comprehensive review of the literature. Arch Pathol Lab Med. 2006;130:857-861. (Pubitemid 43887008)
8. Fletcher CDM, Unni KK, Mertens F. Tumors of Soft Tissue and Bone. Pathology and Genetics. World Health Organization Classification of Tumors. Lyon: IARC Press; 2002.
9. Fukunaga M, Naganuma H, Nikaido T, et al. Extrapleural solitary fibrous tumor: a report of seven cases. Mod Pathol. 1997;10:443-450. (Pubitemid 27244230)
10. Gengler C, Guillou L. Solitary fibrous tumor and haemangiopericytoma: evolution of a concept. Histopathology. 2006;48:63-74.
11. Gold JS, Antonescu CS, Hajdu C, et al. Clinicopathologic correlates of solitary fibrous tumor. Cancer. 2002;94:1057-1068. (Pubitemid 34150861)
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
13. Hanau CA, Miettinen M. Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol. 1995;26:440-449.
14. Hidalgo M. From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin. J Clin Oncol. 2012;30:85-87.
15. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 2010;16:4914-4920.
16. Huang DC, O'Reilly LA, Strasser A, et al. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 1997;16:4628-4638. (Pubitemid 27326600)
17. Jo VY, Mariñ o-Enŕquez A, Fletcher CD. Epithelioid rhabdomyosarcoma: clinicopathologic analysis of 16 cases of a morphologically distinct variant of rhabdomyosarcoma. Am J Surg Pathol. 2011;35: 1523-1530.
18. Kim JH, Jung HW, Kim YS, et al. Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol. 2003;59:47-53; discussion 53-4.17. (Pubitemid 36299107)
19. Macarenco RS, Erickson-Jhonson MR, Wang X, et al. Dedifferentiated solitary fibrous tumours: a clinicopathologic study of 7 cases. Presented at 45th Annual Meeting of the American Society for Clinical Oncology, Orlando, 2009.
20. Magdeleinat P, Alifano M, Petino A, et al. Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment and outcome. Eur J Cardiothorac Surg. 2002;21:1087-1093.
21. Magro G, Emmanuele C, Lopes M, et al. Solitary fibrous tumor with sarcomatous overgrowth. Case report and review of the literature. APMIS. 2008;116:1020-1025.
22. McMaster MJ, Soule EH, Ivins JC. Hemangiopericytoma. A clinicopathologic study and long-term follow-up of 60 patients. Cancer. 1975;36:2232-2244.
23. Mosquera JM, Fletcher CDM. Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component-is this dedifferentiated SFT? Am J Surg Pathol. 2009;33:1314-1321.
24. Muñ oz AK, Berek JS, Fu YS, et al. Pelvic hemangiopericytomas: a report of five cases and literature review. Gynecol Oncol. 1990;36:380-382.
25. Ness GO, Lybaek H, Arnes J, et al. Chromosomal imbalances in a recurrent solitary fibrous tumor of the orbit. Cancer Genet Cytogenet. 2005;162:38-44. (Pubitemid 41278468)
26. Palassini E, Stacchiotti S, Collini P, et al. Solitary fibrous tumor: a retrospective analysis on 65 patients from a reference center. J Clin Oncol. 2009;27:15s. (suppl; abstr 10572).
27. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17:871-879.
28. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci. 2006;31:342-348. (Pubitemid 43903237)
29. Schiariti M, Goetz P, El-Maghraby H, et al. Hemangiopericytoma: long-term outcome revisited. Clinical article. Neurosurg. 2011;114: 747-755.
30. Schirosi L, Lantuejoul S, Cavazza A, et al. Pleuro-pulmonary solitary fibrous tumors. A clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (a/b), c-met, and EGFR. Am J Surg Pathol. 2008;32:1627-1642.
31. Soyuer S, Chang EL, Selek U, et al. Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer. 2004;100:1491-1497. (Pubitemid 38366853)
32. Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and fugitumumab in solitary fibrous tumor (SFT): patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9:1286-1297.
33. Stacchiotti S, Palassini E, Negri T, et al. Antitumor activity of sunitinib malate in solitary fibrous tumors. Ann Oncol. 2010; 21(suppl 8):13470. Abstract.
34. Vallat-Decouvelaere AV, Dry S, Fletcher CDM. Atypical and malignant solitary fibrous tumor in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol. 1998;22:1501-1511. (Pubitemid 28550645)
35. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. 5th ed. Philadelphia: Mosby Elsevier; 2008.
36. Yokoi T, Tsuzuki T, Yatabe Y, et al. Solitary fibrous tumor: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology. 1998;32:423-432. (Pubitemid 28231375)